Vichem was founded in 1999 as a highly specialized Biotechnology Company in developing kinase inhibitors. The CEO of the company is Prof. Dr. György Kéri. Vichem provides Medicinal Chemistry and drug discovery services based on our unique, in-house developed Nested Chemical Library™ (NCL) technology, supported by the KinaTor™technology. The NCL was designed on the platform of knowledge base what we have built up from our experience accumulated in the recent 20 years of kinase inhibitory chemistry. Vichem has great expertise in drug like lead optimization.

Vichem provides novel chemical inhibitors of cellular kinases, initially for the Helicobacter Pylori and the Epstein-Barr Virus project. Nested Chemical Library™ technology and pharmacophore modeling are applied for the development of preclinical lead molecules acting on the selected tyrosin/ser-thr. kinases (e.g. EGFR, cMet, p38, Akt, ERK etc.) and Cox2 target molecules or against any new targets identified in the project, which may be involved in the Helicobacter Pylori or the Epstein-Barr Virus activated signal transduction pathways.

Szantai-Kis, C; Kovesdi, I; Eros, D; et al. Prediction oriented QSAR modelling of EGFR inhibition CURRENT MEDICINAL CHEMISTRY, 13 (3): 277-287 2006 Keri, G; Szekelyhidi, Z; Banhegyi, P; et al. Drug discovery in the kinase inhibitory field using the Nested Chemical Library (TM) technology ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 3 (5): 543-551 OCT 2005 Godl, K; Gruss, OJ; Eickhoff, J; et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signalling CANCER RESEARCH, 65 (15): 6919-6926 AUG 1 2005 Szekelyhidi, Z; Pato, J; Waczek, F; et al. Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 15 (13): 3241-3246 JUL 1 2005 Elkind, NB; Szentpetery, Z; Apati, A; et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) CANCER RESEARCH, 65 (5): 1770-1777 MAR 1 2005 Orfi, L; Szantai-Kis, C; Eros, D; et al. Development of a general QSAR model of EGFR inhibition EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 23: S35-S35 Suppl. 1 OCT 2004 Eros, D; Keri, G; Kovesdi, I; et al. Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods MINI-REVIEWS IN MEDICINAL CHEMISTRY, 4 (2): 167-177 FEB 2004 Szakacs, Z; Beni, S; Varga, Z; et al. Acid-base profiling of imatinib (Gleevec) and its fragments JOURNAL OF MEDICINAL CHEMISTRY, 48 (1): 249-255 JAN 13 2005 Buschbeck, M; Hofbauer, S; Di Croce, L; et al. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival EMBO REPORTS, 6 (1): 63-69 JAN 2005 Brehmer, D; Greff, Z; Godl, K; et al. Cellular targets of gefitinib CANCER RESEARCH, 65 (2): 379-382 JAN 15 2005